Literature DB >> 8272406

Plasma pharmacokinetics of lactone and carboxylate forms of 20(S)-camptothecin in anesthetized rats.

D O Scott1, D S Bindra, V J Stella.   

Abstract

20(S)-Camptothecin exists in equilibrium between its lactone (CPT) and its carboxylate forms (Na-CPT) under stimulated physiological conditions, with the equilibrium favoring the carboxylate form. The rates of lactone hydrolysis were studied in plasma, serum albumin, and blood and were found to be faster than in aqueous buffers at equivalent pH values. From mechanistic information and in vivo activity data, the lactone appears to be the active form of the drug. It has been argued, therefore, that if an equilibrium existed between the lactone and the carboxylate, Na-CPT could be used to deliver the lactone effectively. In the present study, plasma pharmacokinetics were performed in sodium pentobarbital-anesthetized rats treated with both CPT (lactone) and the sodium salt of camptothecin (carboxylate, Na-CPT) and the lactone and carboxylate, as well as the total drug, concentration versus time profiles were assessed. It was found that plasma concentrations and AUC values for the lactone were significantly higher after dosing with CPT than after dosing with Na-CPT. After i.v. administration, the ratio of plasma lactone to carboxylate was skewed by the apparent rapid and extensive uptake of the lactone into tissues and the rapid clearance of both species. From our results, it appears that the lower in vivo activity of Na-CPT compared to that from CPT administration might be attributed to the altered conversion of carboxylate into lactone in vivo compared to that predicted from in vitro data.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8272406     DOI: 10.1023/a:1018919224450

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  17 in total

1.  Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection.

Authors:  J P Loh; A E Ahmed
Journal:  J Chromatogr       Date:  1990-09-14

2.  Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

3.  High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma.

Authors:  J H Beijnen; B R Smith; W J Keijer; R van Gijn; W W ten Bokkel Huinink; L T Vlasveld; S Rodenhuis; W J Underberg
Journal:  J Pharm Biomed Anal       Date:  1990       Impact factor: 3.935

Review 4.  DNA topoisomerase poisons as antitumor drugs.

Authors:  L F Liu
Journal:  Annu Rev Biochem       Date:  1989       Impact factor: 23.643

5.  Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity.

Authors:  P J Creaven; L M Allen; F M Muggia
Journal:  Cancer Chemother Rep       Date:  1972-10

6.  Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity.

Authors:  R P Hertzberg; M J Caranfa; K G Holden; D R Jakas; G Gallagher; M R Mattern; S M Mong; J O Bartus; R K Johnson; W D Kingsbury
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

7.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.

Authors:  C Jaxel; K W Kohn; M C Wani; M E Wall; Y Pommier
Journal:  Cancer Res       Date:  1989-03-15       Impact factor: 12.701

8.  On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex.

Authors:  R P Hertzberg; M J Caranfa; S M Hecht
Journal:  Biochemistry       Date:  1989-05-30       Impact factor: 3.162

9.  DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.

Authors:  Y H Hsiang; L F Liu; M E Wall; M C Wani; A W Nicholas; G Manikumar; S Kirschenbaum; R Silber; M Potmesil
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

10.  A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues.

Authors:  J Fassberg; V J Stella
Journal:  J Pharm Sci       Date:  1992-07       Impact factor: 3.534

View more
  15 in total

1.  Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Authors:  Rajendra S Kadam; David W A Bourne; Uday B Kompella
Journal:  Drug Metab Dispos       Date:  2012-04-12       Impact factor: 3.922

Review 2.  Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine.

Authors:  Michael W Ambrogio; Courtney R Thomas; Yan-Li Zhao; Jeffrey I Zink; J Fraser Stoddart
Journal:  Acc Chem Res       Date:  2011-06-15       Impact factor: 22.384

3.  Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Authors:  K Arimori; N Kuroki; A Kumamoto; N Tanoue; M Nakano; E Kumazawa; A Tohgo; M Kikuchi
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

4.  Soluplus--solubilized citrated camptothecin--a potential drug delivery strategy in colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Daniel Bar-Shalom; André Huss Eriksson; Dipak K Majumdar
Journal:  AAPS PharmSciTech       Date:  2011-11-22       Impact factor: 3.246

5.  A method to determine the incorporation capacity of camptothecin in liposomes.

Authors:  Ann Mari Saetern; Gøril Eide Flaten; Martin Brandl
Journal:  AAPS PharmSciTech       Date:  2004-06-17       Impact factor: 3.246

6.  Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67.

Authors:  Eyob D Adane; Zhiwei Liu; Tian-Xiang Xiang; Bradley D Anderson; Markos Leggas
Journal:  Pharm Res       Date:  2010-04-29       Impact factor: 4.200

7.  The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.

Authors:  B E Davies; E A Minthorn; M J Dennis; H Rosing; J H Beijnen
Journal:  Pharm Res       Date:  1997-10       Impact factor: 4.200

8.  Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitors.

Authors:  Yunlong Song; Zhiyu Shao; Thomas S Dexheimer; Evan S Scher; Yves Pommier; Mark Cushman
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

9.  Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model.

Authors:  Piyun Chao; Manjeet Deshmukh; Hilliard L Kutscher; Dayuan Gao; Sujata Sundara Rajan; Peidi Hu; Debra L Laskin; Stanley Stein; Patrick J Sinko
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

10.  Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin.

Authors:  S Sadekar; G Thiagarajan; K Bartlett; D Hubbard; A Ray; L D McGill; H Ghandehari
Journal:  Int J Pharm       Date:  2013-08-08       Impact factor: 5.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.